Merck’s Phase 3 Trials Show DOR/ISL Maintains HIV-1 Suppression at 48 Weeks Merck, known as MSD outside of the United States and Canada, has announced promising results from two pivotal Phase 3 clinical trials evaluating its investigational, once-daily, oral, two-drug…
Gilead Unveils New HIV Treatment Data at CROI 2025 Gilead Sciences, Inc. has unveiled a significant array of late-breaking data and multiple oral presentations from its groundbreaking HIV treatment portfolio and pipeline at the Conference on Retroviruses and Opportunistic Infections…
PharmaCord & Mercalis Merge to Advance Biopharma Solutions PharmaCord LLC (“PharmaCord”), a leading provider of patient services for the biopharmaceutical industry, and Mercalis, an integrated life sciences commercialization partner, have announced a merger to create one of the largest independent…
InTandem Capital Invests in Clinilabs InTandem Capital Partners (“InTandem Capital” or the “Firm”), a private equity firm specializing in healthcare services, has officially announced its strategic partnership with Clinilabs (the “Company”). Clinilabs is a global, full-service contract research organization (CRO)…
Generative AI Revolutionizes Health Technology Assessment Landscape: Trinity Life Sciences Enhances HTA Vision Trinity Life Sciences, a leading provider of strategy, insights, and analytics for the life sciences industry, has announced a groundbreaking enhancement to its HTA Vision platform. The…
Cellino and Matricelf Partner to Scale Personalized Spinal Cord Injury Treatments Cellino and Matricelf (TASE: MTLF) announced today a groundbreaking global collaboration aimed at accelerating the biomanufacturing of personalized spinal cord injury treatments. This partnership integrates Cellino’s cutting-edge Nebula™ technology…
Twist Bioscience Announces Expedited Delivery for Academic Orders of Twist Express Genes at No Additional Cost Twist Bioscience Corporation (NASDAQ: TWST), a leading mid-cap growth and value equity company operating in the life sciences sector of the healthcare industry, has…
NationsBenefits® Partners with TS Emporium to Expand Access to Culturally Relevant Health Products NationsBenefits®, a leading provider of supplemental benefits and healthcare fintech solutions, has announced a strategic partnership with TS Emporium, a well-established provider of Asian-focused food, wellness, and…
UroGen Pharma Reports Inducement Grants Under Nasdaq Rule 5635(c)(4) UroGen Pharma Ltd. (Nasdaq: URGN), a leading biotechnology company focused on developing and commercializing innovative therapies for urothelial and specialty cancers, has announced the issuance of inducement restricted stock units (“RSUs”)…
NovaBay Pharmaceuticals Announces Special Stockholders Meeting NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (“NovaBay” or the “Company”) has officially announced the scheduling of a virtual Special Meeting on April 16, 2025. During this meeting, stockholders will vote on a proposal concerning…
ENCell’s EN001 Granted FDA Orphan Drug Designation for Charcot-Marie-Tooth Disease ENCell, a pioneering biopharmaceutical company specializing in cell and gene therapy CDMO and novel drug development, announced that its investigational drug EN001 has received Orphan Drug Designation (ODD) from the…
Ventus Therapeutics Showcases Caspase-4/5 as Key Therapeutic Targets in Nature Reviews Immunology Ventus Therapeutics, a clinical-stage biopharmaceutical company focused on advancing innovative small-molecule therapies for immunological, inflammatory, and neurological disorders, has announced a significant publication in the prestigious peer-reviewed journal…